Metronomic administration of the drug GMX1777, a cellular NAD synthesis inhibitor, results in neuroblastoma regression and vessel maturation without inducing drug resistance

International Journal of Cancer

Volumn 126, Issue 12, 2010, Pages 2773-2789

  Fuchs, Dieter ^a   Rodriguez, Alejandro ^a   Eriksson, Sara ^a   Christofferson, Rolf ^a,b   Sundberg, Christian ^a,b   Azarbayjani, Faranak ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; Drug resistance; Energy; Neuroblastoma; Pericyte; Relapse; Stroma; Tumor; Vessel maturation

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE TRANSPORTER 1; GMX 1777; GMX 1778; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; UNCLASSIFIED DRUG; VASCULOTROPIN A; 1 (2 (2 (2 (2 METHOXYETHOXY)ETHOXY)ETHOXY)ETHOXYCARBONYLOXYMETHYL) 4 (N' CYANO N'' (6 (4 CHLOROPHENOXY)HEXYL) N GUANIDINO)PYRIDINIUM; 1-(2-(2-(2-(2-METHOXYETHOXY)ETHOXY)ETHOXY)ETHOXYCARBONYLOXYMETHYL)-4-(N'-CYANO-N''-(6-(4-CHLOROPHENOXY)HEXYL)-N-GUANIDINO)PYRIDINIUM; GUANIDINE DERIVATIVE; MYCN PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NUCLEAR PROTEIN; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RELAPSE; CANCER RISK; CELL COMPARTMENTALIZATION; CELL DENSITY; CELL ENERGY; CELL EXPANSION; CELL INFILTRATION; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STROMA; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION; TUMOR RESISTANCE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; IMMUNOBLOTTING; METABOLISM; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL CULTURE; VASCULARIZATION;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GUANIDINES; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED BALB C; MICE, SCID; NAD; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951932803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25206     Document Type: Article

References (73)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369: 2106-2120
2. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994;54: 5036-5040 (Pubitemid 24313471)
3. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. New Engl J Med 1996; 334:231-238 (Pubitemid 26032215)
4. Mimeault M, Hauke R, Batra SK. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 2008;83:673-691 (Pubitemid 351559599)
5. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, Imeson J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 2000;36:901-908
6. Pedersen PL. The cancer cell's "power plants" as promising therapeutic targets: an overview. J Bioenerg Biomembr 2007;39: 1-12.
7. Fuchs D, Christofferson R, Stridsberg M, Lindhagen E, Azarbayjani F. Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. J Transl Med 2009;7:16-27.
8. Hjarnaa PJ, Jonsson E, Latini S, Dhar S, Larsson R, Bramm E, Skov T, Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo. Cancer Res 1999;59:5751-5757
9. Olesen UH, Christensen MK, Bjorkling F, Jaattela M, Jensen PB, Sehested M, Nielsen SJ. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804.
10. Huttermann M, Lee I, Pecinova A, Pecina P, Przyklenk K, Doan JW. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J Bioenerg Biomembr 2008;40:445-456
11. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008;13:472-482 (Pubitemid 351766797)
12. De Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero Di Montezemolo L, Donfrancesco A, Pession A, Provenzi M, di Cataldo A, Rizzo A, Tonini GP, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003;21:1592-1601
13. Hafner C, Reichle A, Vogt T. New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPAR gamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 2005;5:393-419.
14. Zaizen Y, Taniguchi S, Suita S. The role of cellular motility in the invasion of human neuroblastoma cells with or without N-myc amplification and expression. J Pediatr Surg 1998;33:1765-1770
15. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protoc 2008;3:1364-1369
16. Wassberg E, Pahlman S, Westlin JE, Christofferson R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 1997;41:327-333
17. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940
18. Schlingemann RO, Rietveld FJR, de Waal RMW, Ferrone S, Ruiter DJ. Expression of the high molecular weight-melanoma associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol 1990;136: 1393-1405 (Pubitemid 20210338)
19. Levine JM, Nishiyama A. The NG2 chondroitin sulfate proteoglycan: a multifunctional proteoglycan associated with immature cells. Perspect Dev Neurobiol 1996;3:245-259 (Pubitemid 126839134)
20. Sundberg C, Ljungstrom M, Lindmark G, Gerdin B, Rubin K. Microvascular pericytes express platelet-derived growth factor-β receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol 1993;143:1377-1388 (Pubitemid 24057108)
21. Schlingemann RO, Rietveld FJR, Kwaspen F, van der Kerkhof FPC, de waal MW, Ruiter DJ. Differential expression of markers for endothelial cells, pericytes and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 1991;138:1335-1347
22. Skalli O, Ropraz P, Trzeciak A, Benzonona G, Gilessen D, Gabbiani G. A monoclonal antibody against α-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 1986;103: 2787-2796 (Pubitemid 17008024)
23. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 1990;43:752-757 (Pubitemid 20279705)
24. Ianaro A, Cicala C, Calignano A, Koteliansky V, Gotwals P, Bucci M, Gerli R, Santucci L, Fiorucci S, Cirino G. Anti-very late antigen-1 monoclonal antibody modulates the development of secondary lesion and T-cell response in experimental arthritis. Lab Invest 2000;80:73-80. (Pubitemid 30067382)
25. van Muijen GN, Ruiter DJ, Warnaar SO. Coexpression of intermediate filament polypeptides in human fetal and adult tissues. Lab Invest 1987;57:359-369
26. Smith ME, Holgate CS, Williamson JM, Grigor I, Quirke P, Bird CC. Major histocompatibility complex class II antigen expression in B and T cell non-hodgkin's lymphoma. J Clin Pathol 1987;40:34-41. (Pubitemid 17234275)
27. Jackson DG. The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends Cardiovasc Med 2003;13: 1-7.
28. Sundberg C, Nagy JA, Brown LF, Feng D, Eckelhoefer IA, Manseau EJ, Dvorak AM, Dvorak HF. Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol 2001;158:1145-1160
29. Rodriguez A, Karen J, Gardner H, Gerdin B, Rubin K, Sundberg C. Integrin α1β1 is involved in the differentiation into myofibroblasts in adult reactive tissues in vivo. J Cell Mol Med 2009;13:3449-3462
30. Wassberg E, Hedborg F, Skoldenberg E, Stridsberg M, Christofferson R. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 1999;154: 395-403.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25: 402-408
32. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 2004;299:286-293
33. Rojiani AM, Dorovini-Zis K. Glomeruloid vascular structures in glioblastoma multiforme: an immunohistochemical and ultrastructural study. J Neurosurg 1996;85: 1078-1084
34. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau EJ, Harvey VS, Eckelhoefer IA, Feng D, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000; 80:99-115.
35. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-693
36. Skalli O, Gabbiani G. The biology of the myofibroblast: relationship to wound contraction and fibrocontractive diseases. The molecular and cellular biology of wound repair. New York: Plenum Publishing Corp, 1988. 373-402.
37. Airley RE, Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53: 233-256
38. Mobasheri A, Richardson S, Mobasheri R, Shakibaei M, Hoyland JA. Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. Histol Histopathol 2005;20: 1327-1338
39. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-662 (Pubitemid 40175840)
40. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J 2008;22:659-661 (Pubitemid 351348146)
41. Svensson A, Backman U, Jonsson E, Larsson R, Christofferson R. CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res 2002;51: 607-611 (Pubitemid 34453578)
42. Binderup E, Bjorkling F, Hjarnaa PV, Latini S, Baltzer B, Carlsen M, Binderup L. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg Med Chem Lett 2005;15:2491-2494
43. Blaheta RA, Daher FH, Michaelis M, Hasenberg C, Weich EM, Jonas D, Kotchetkov R, Doerr HW, Cinatl J Jr. Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC cancer 2006;6:294-307.
44. Russell J, Wheldon TE, Stanton P. A radioresistant variant derived from a human neuroblastoma cell line is less prone to radiation-induced apoptosis. Cancer Res 1995;55:4915-4921
45. Ireland CM, Pittman SM, Jones SL, Harnett PR. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines. Anticancer Res 1994;14:2397-2403
46. Livingstone A, Mairs RJ, Russell J, O'Donoghue J, Gaze MN, Wheldon TE. N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatment. Eur J Cancer 1994;30A:382-389
47. Brat DJ, Mapstone TB. Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression. Ann Intern Med 2003;138:659-668
48. Wesseling P, Schlingemann RO, Rietveld FJ, Link M, Burger PC, Ruiter DJ. Early and extensive contribution of pericytes/ vascular smooth muscle cells to microvascular proliferation in glioblastoma multiforme: an immuno-light and immuno-electron microscopic study. J Neuropathol Exp Neurol 1995;54:304-310
49. Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol 2008;2:41-53.
50. Yoshida D, Kim K, Noha M, Teramoto A. Hypoxia inducible factor 1-α regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol 2006;76: 13-21.
51. Holmquist L, Lofstedt T, Pahlman S. Effect of hypoxia on the tumor phenotype: the neuroblastoma and breast cancer models. Adv Exp Med Biol 2006;587:179-193
52. Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell 2005;7:513-520
53. Zeine R, Salwen HR, Peddinti R, Tian Y, Guerrero L, Yang Q, Chlenski A, Cohn SL. Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. Mod Pathol 2009;22:950-958
54. Liu S, Tian Y, Chlenski A, Yang Q, Zage P, Salwen HR, Crawford SE, Cohn SL. Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts. Am J Pathol 2005;166:891-900.
55. Liu S, Tian Y, Chlenski A, Yang Q, Salwen HR, Cohn SL. 'Cross-talk' between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis. Cancer Lett 2005;228:125-131
56. Mueller MM, Fusenig NE. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells. Differentiation 2002;70:486-497
57. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-371
58. Sundberg C, Friman T, Hecht LE, Kuhl C, Solomon KR. Two different PDGF beta-receptor cohorts in human pericytes mediate distinct biological endpoints. Am J Pathol 2009;175:171-189
59. Sundberg C, Kowanetz M, Brown LF, Detmar M, Dvorak HF. Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo. Lab Invest 2002;82: 387-401.
60. Sundberg C, Ivarsson M, Gerdin B, Rubin K. Pericytes as collagen producing cells in excessive dermal scarring. Lab Invest 1996; 74:452-466
61. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:1501-1506
62. Lucas T, Abraham D, Aharinejad S. Modulation of tumor associated macrophages in solid tumors. Front Biosci 2008;13:5580-5588
63. Salnikov AV, Roswall P, Sundberg C, Gardner H, Heldin NE, Rubin K. Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma. Lab Invest 2005;85:512-521
64. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3: 23-35.
65. Seemayer TA, Lagace R, Schurch W, Tremblay G. Myofibroblasts in the stroma of invasive and metastatic carcinoma: a possible host response to neoplasia. Am J Surg Pathol 1979;3:525-533
66. Skalli O, Schurch W, Seemayer T, Lagace R, Montandon D, Pittet B, Gabbiani G. Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab Invest 1989;60: 275-285
67. Ivarsson M, Sundberg C, Farrokhnia N, Pertoft H, Rubin K, Gerdin B. Recruitment of type I collagen producing cells from the microvasculature in vitro. Exp Cell Res 1996;229:336-349
68. Ronnov-Jessen L, Petersen OW, Koteliansky VE, Bissel MJ. The origin of myofibroblasts in breast cancer. J Clin Invest 1995;95:859-873
69. Crocker DJ, Murad TM, Geer JP. The role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol 1970; 13:51-65.
70. Dore-Duffy P, Owen C, Balabanov R, Murphy S, Beaumont T, Rafols JA. Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 2000;60: 55-69.
71. Crosby JR, Tappan KA, Seifert RA, Bowen-Pope DF. Chimeric analysis reveals that fibroblasts and endothelial cells require platelet-derived growth factor receptor β expression for participation in reactive connective tissue formation in adults but not during development. Am J Pathol 1999;154:1315-1321
72. Naumov GN, Folkman J, Straume O, Akslen LA. Tumor-vascular interactions and tumor dormancy. Apmis 2008;116: 569-585
73. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153